These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 20222822)
1. Benefits of and safety concerns associated with drug-eluting coronary stents. Garg S; Serruys P Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):449-70. PubMed ID: 20222822 [TBL] [Abstract][Full Text] [Related]
2. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries. Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397 [TBL] [Abstract][Full Text] [Related]
3. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939 [TBL] [Abstract][Full Text] [Related]
4. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255 [TBL] [Abstract][Full Text] [Related]
5. Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare-metal stents. De Labriolle A; Bonello L; Lemesle G; Steinberg DH; Roy P; Xue Z; Kaneshige K; Suddath WO; Satler LF; Kent KM; Pichard AD; Lindsay J; Waksman R Arch Cardiovasc Dis; 2009 Mar; 102(3):209-17. PubMed ID: 19375675 [TBL] [Abstract][Full Text] [Related]
6. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous late stent thrombosis of drug-eluting stents causing acute anterior and inferior myocardial infarction. Arora N; Aggarwal K J Invasive Cardiol; 2008 Jan; 20(1):E14-7. PubMed ID: 18174623 [No Abstract] [Full Text] [Related]
8. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. Stone GW; Lansky AJ; Pocock SJ; Gersh BJ; Dangas G; Wong SC; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Möckel M; Ochala A; Kellock A; Parise H; Mehran R; N Engl J Med; 2009 May; 360(19):1946-59. PubMed ID: 19420364 [TBL] [Abstract][Full Text] [Related]
9. Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents? Valgimigli M; Airoldi F; Zimarino M J Cardiovasc Med (Hagerstown); 2009 Oct; 10 Suppl 1():S17-26. PubMed ID: 19851216 [TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial. Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029 [TBL] [Abstract][Full Text] [Related]
11. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G; JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420 [TBL] [Abstract][Full Text] [Related]
12. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925 [TBL] [Abstract][Full Text] [Related]
13. Very late thrombosis of a drug-eluting stent deployed during primary angioplasty for ST-elevation myocardial infarction. Rigattieri S; Patrizi R; Silvestri P; Di Russo C; Musto C; Ferraiuolo G; Palamara A; Loschiavo P J Cardiovasc Med (Hagerstown); 2006 Oct; 7(10):771-4. PubMed ID: 17001240 [TBL] [Abstract][Full Text] [Related]
14. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. Brodie B; Pokharel Y; Garg A; Kissling G; Hansen C; Milks S; Cooper M; McAlhany C; Stuckey T JACC Cardiovasc Interv; 2012 Oct; 5(10):1043-51. PubMed ID: 23078734 [TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of drug eluting stent in patients with ST elevation myocardial infarction undergoing primary angioplasty. Romano M; Buffoli F; Tomasi L; Corrado L; Ferrari MR; Zanini R Catheter Cardiovasc Interv; 2008 May; 71(6):759-63. PubMed ID: 18412066 [TBL] [Abstract][Full Text] [Related]
17. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625 [TBL] [Abstract][Full Text] [Related]
18. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959 [TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. James SK; Stenestrand U; Lindbäck J; Carlsson J; Scherstén F; Nilsson T; Wallentin L; Lagerqvist B; N Engl J Med; 2009 May; 360(19):1933-45. PubMed ID: 19420363 [TBL] [Abstract][Full Text] [Related]
20. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Mehran R; Brodie B; Cox DA; Grines CL; Rutherford B; Bhatt DL; Dangas G; Feit F; Ohman EM; Parise H; Fahy M; Lansky AJ; Stone GW Am Heart J; 2008 Jul; 156(1):44-56. PubMed ID: 18585496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]